Últimas noticias sobre MKS (NASDAQ:MKSI) Bolsa

MKS INC

MKS Instruments

MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.

Mizuho analyst Vijay Rakesh maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Outperform and raises the price target from $105 to $118.

News

Price Target

Analyst Ratings

MKSI

Mizuho Maintains Outperform on MKS, Raises Price Target to $118

In the last three months, 6 analysts have published ratings on MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $107.17, a high estimate of $140.00, and a low estimate of $90.00. Observing a 3.45% increase, the current average has risen from the previous average price target of $103.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1752152459_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive MKS. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MKS. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MKS compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MKS's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MKS's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MKSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MKS analyst ratings.</a>
<h2>About MKS</h2>
MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
<h3>MKS: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: MKS displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 7.83%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: MKS's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MKS's ROA stands out, surpassing industry averages. With an impressive ROA of 0.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.0, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into MKS Stock: Analyst Perspectives (6 Ratings)

Goldman Sachs analyst James Schneider initiates coverage on MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Sell rating and announces Price Target of $90.

Initiation

Goldman Sachs Initiates Coverage On MKS with Sell Rating, Announces Price Target of $90

Wells Fargo analyst Joseph Quatrochi maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Equal-Weight and raises the price target from $85 to $100.

Wells Fargo Maintains Equal-Weight on MKS, Raises Price Target to $100

Across the recent three months, 4 analysts have shared their insights on MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $113.25, with a high estimate of $140.00 and a low estimate of $93.00. Marking an increase of 4.62%, the current average surpasses the previous average price target of $108.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1750773675_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive MKS is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MKS. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of MKS compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for MKS's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into MKS's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MKSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MKS analyst ratings.</a>
<h2>Unveiling the Story Behind MKS</h2>
MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
<h3>Understanding the Numbers: MKS's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, MKS showcased positive performance, achieving a revenue growth rate of 7.83% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: MKS's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MKS's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.22%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.61%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: MKS's debt-to-equity ratio surpasses industry norms, standing at 2.0. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About MKS Stock

Cantor Fitzgerald analyst Matthew Prisco maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $110 to $120.

Cantor Fitzgerald Maintains Overweight on MKS, Raises Price Target to $120

WIIM

ACLS

ALAR

ALGM

AMBA

AMKR

AOSL

AVGO

BZAI

CEVA

CRDO

DIOD

ENTG

KLIC

MCHP

MOBX

MPWR

NVDA

NVTS

NXPI

OLED

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

WOLF

Shares of several semiconductor companies are trading higher amid GlobalFoundries' announcement to commit $16 billion towards US chip expansion, which may be buoying investor sentiment towards the space.

Morgan Stanley analyst Joseph Moore maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $93 to $100.

Morgan Stanley Maintains Overweight on MKS, Raises Price Target to $100

MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) ("MKS"), a global provider of enabling technologies that transform our world, announced today that James A. Schreiner will conclude his tenure as the leader of the Materials Solutions Division ("MSD") on August 1, 2025, and will transition back to his role as Executive Vice President &amp; Chief Operating Officer of MKS. In this position, Mr. Schreiner will lead operations, supply chain, and workplace operations for the Vacuum Solutions Division and the Photonics Solutions Division.
The Company also announced that David P. Henry, the Company's current Executive Vice President, Operations and Corporate Marketing, will assume the role of Executive Vice President, Global Strategic Marketing, and General Manager, Materials Solutions Division, on August 1, 2025. In this role, Mr. Henry will succeed Mr. Schreiner as the leader of MSD as well as maintain responsibility for strategic and corporate marketing for the Company.

Management

MKS Instruments Announces Leadership Transition As James A. Schreiner To Step Down From Materials Solutions Division On August 1, 2025 And Will Transition Back To His Role As Executive Vice President & COO

The Company's stock will continue to trade on Nasdaq under its current symbol "MKSI" and the name change will have no effect on MKS' corporate structure or the names of any of its subsidiaries.

MKS Instruments Changes Name To MKS Inc.

ACMR

ALAB

ATOM

AXTI

CRUS

CSIQ

FORM

FSLR

GCTS

HIMX

ICHR

INDI

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MTSI

NVMI

Penguin Solutions, Inc. - Ordinary Shares

PENG

POWI

QRVO

RGTI

SITM

SLAB

SMTC

SWKS

SYNA

UCTT

VECO

Shares of semiconductor companies are higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A reduction in tariffs could alleviate some supply chain concerns and improve macro sentiment as well as demand visibility.

Morgan Stanley analyst Joseph Moore maintains MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $85 to $93.

Morgan Stanley Maintains Overweight on MKS Instruments, Raises Price Target to $93

Analysts' ratings for MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $139.33, a high estimate of $147.00, and a low estimate of $129.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.91%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746795637_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of MKS Instruments among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$129.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MKS Instruments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MKS Instruments compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of MKS Instruments's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into MKS Instruments's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MKSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MKS Instruments analyst ratings.</a>
<h2>Delving into MKS Instruments's Background</h2>
MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
<h3>Breaking Down MKS Instruments's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining MKS Instruments's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.71% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: MKS Instruments's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): MKS Instruments's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.86%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): MKS Instruments's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: MKS Instruments's debt-to-equity ratio surpasses industry norms, standing at 2.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: MKS Instruments In The Eyes Of 6 Experts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $145 to $140. Needham analyst James Ricchiuti maintained a Buy rating. MKS Instruments shares closed at $77.29 on Thursday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) from $7 to $5. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. Draganfly shares closed at $1.89 on Thursday. <a href="https://www.benzinga.com/quote/DPRO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) price target from $130 to $179. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Dave shares closed at $152.73 on Thursday. <a href="https://www.benzinga.com/quote/DAVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital increased the price target for Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) from $28 to $33. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. Oculis Holding shares closed at $18.70 on Thursday. <a href="https://www.benzinga.com/quote/OCS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for Vital Farms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) from $52 to $46. Telsey Advisory Group analyst Sarang Vora maintained an Outperform rating. Vital Farms shares closed at $32.57 on Thursday. <a href="https://www.benzinga.com/quote/VITL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) price target from $15 to $7. JP Morgan analyst Robbie Marcus downgraded the stock from Neutral to Underweight. CVRx shares settled at $7.78 on Thursday. <a href="https://www.benzinga.com/quote/CVRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham slashed CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) price target from $45 to $39. Needham analyst Chris Pierce maintained a Buy rating. CarGurus shares closed at $27.95 on Thursday. <a href="https://www.benzinga.com/quote/CARG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) price target from $45 to $40. Wells Fargo analyst Gabe Hajde downgraded the stock from Equal-Weight to Underweight. International Paper shares closed at $44.92 on Thursday.  <a href="https://www.benzinga.com/quote/IP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed the price target for Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) from $32 to $20. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Iovance Biotherapeutics shares settled at $3.17 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this</a><a href="https://www.benzinga.com/quote/IOVA/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Wells Fargo cut Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) price target from $205 to $180. Wells Fargo analyst Gabe Hajde downgraded the stock from Overweight to Equal-Weight. Packaging Corporation shares closed at $183.42 on Thursday. <a href="https://www.benzinga.com/quote/PKG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DAVE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09075444/image-104-1024x577.png" alt="" class="wp-image-910007" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09075444/image-104-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09075444/image-104-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09075444/image-104-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09075444/image-104.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

CARG

CVRX

DAVE

DPRO

IOVA

VITL

Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday

Needham analyst James Ricchiuti maintains MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Buy and lowers the price target from $145 to $140.

Needham Maintains Buy on MKS Instruments, Lowers Price Target to $140

Second Quarter 2025 Guidance
<ul>
<li>Revenue of $925 million, plus or minus $40 million</li>
<li>Gross margin of 46.5%, plus or minus 1.0%</li>
<li>GAAP operating expenses of $316 million, plus or minus $5 million and Non-GAAP operating expenses of $252 million, plus or minus $5 million</li>
<li>GAAP net income of $55 million, plus or minus $21 million and Non-GAAP net earnings of $106 million, plus or minus $19 million</li>
<li>GAAP net income per diluted share of $0.81, plus or minus $0.32 and Non-GAAP net earnings per diluted share of $1.56, plus or minus $0.28</li>
<li>Adjusted EBITDA of $216 million, plus or minus $23 million</li>
</ul>

Guidance

MKS Instruments Sees Q2 GAAP EPS $0.49-$1.13 vs $1.12 Est

MKS Instruments Sees Q2 Adj EPS $1.28-$1.84 vs $1.66 Est; Sees Sales $885.000M-$965.000M vs $937.59M Est

MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $1.44 by 18.75 percent. This is a 44.92 percent increase over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $936.00 million which beat the analyst consensus estimate of $913.58 million by 2.45 percent. This is a 7.83 percent increase over sales of $868.00 million the same period last year.

Earnings

Earnings Beats

MKS Instruments Q1 Adj. EPS $1.71 Beats $1.44 Estimate, Sales $936.00M Beat $913.58M Estimate

MKS Instruments. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) ("MKS"), a global provider of enabling technologies that transform our world, announced today the groundbreaking of its cutting-edge Atotech chemical manufacturing and TechCenter facility at the Asia Industrial Estate Suvarnabhumi, located east of Bangkok, Thailand. This strategic investment aligns with MKS' commitment to grow alongside its customers and deliver localized expertise to accelerate technological advancements across the region. The new facility also underscores MKS' dedication to fostering Thailand's growing role within the printed circuit board ("PCB") industry.

MKS Instruments Breaks Ground On Atotech Chemical Manufacturing Facility In Thailand

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Press Releases

MKS Instruments Announces First Quarter 2025 Earnings Conference Call

MKS Instruments to Participate in JP Morgan's 53rd Annual Global Technology, Media and Communications Conference

General

MKS Breaks Ground on New Chemical Manufacturing and TechCenter Facility in Thailand

MKS Instruments Reports First Quarter 2025 Financial Results

Dividends

MKS Instruments Declares Quarterly Cash Dividend

MKS Instruments Announces Change of Corporate Name to MKS Inc.

MKS Instruments Announces Senior Leadership Appointments

MKS Named in U.S. News & World Report's 2025-2026 Best Companies to Work For

MKS Named by Time as One of America's Best Mid-Sized Companies

MKS Inc. Announces Second Quarter 2025 Earnings Conference Call

Axcelis Technologies, Inc. - Common Stock

Axcelis Technologies

ACM Research, Inc. - Class A Common Stock

ACM Research

Aehr Test System

Aeluma

Applied Mat

Amkor Tech

ASML Holding N.V. - New York Registry Shares

ASML Holding

Atomera

Cohu

DAQO New Energy Corp. American Depositary Shares, each representing five ordinary shares

Daqo New Energy

Enphase Energy

Entegris

Comments

MKS

Noticias

Últimas noticias sobre MKS (NASDAQ:MKSI) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL